Cellyan Biotechnology Co., Ltd
corporate_fare Company Profile
Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 8 items for HKPD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-10, rated 8/10. Across its 8 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for HKPD spans 6-K, 20-F, F-3, F-1.
Recent high-impact activity:
- Cellyan Biotechnology Proposes 1-for-20 Reverse Split to Regain Nasdaq Compliance
- Cellyan Biotechnology 20-F Flags Going Concern Doubt, 34% Revenue Plunge, and Nasdaq Delisting Threat
- Cellyan Biotechnology Secures Nasdaq Extension to January 2027 for $1 Bid Price Compliance; Reverse Split Under Consideration
- Cellyan Biotechnology Files $200M Shelf Registration Amid Nasdaq Delisting Threat
- Cellyan Biotechnology Files for Resale of 12.5M Shares and 25M Warrants from Deeply Discounted Private Placement
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for HKPD, detected from its recent SEC filings · based on capital-structure filings through 2026-06-12.
$200 Million Shelf Registration · Massive Potential Dilution
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
HKPD files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.